Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of G03-52-01 in Healthy Adults
NCT04171115Phase 1Completed
- Sponsor
- Resilience Government Services
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of G03-52-01 in botulism (4 cohorts), sponsored by Resilience Government Services. Primary endpoints: Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 at Day 120, Occurrence of Adverse Events (AE) Following Administration of G03-52-01 at Day 120 and 1 more. Started Jun 2020; status: completed.
02
Drugs
G03-52-01
03
Conditions
botulism
Beyond the preview
Go deeper on NCT04171115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171115.